Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Martingale Labs Inc. currently faces 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by a distinct examiner and is located in a distinct art unit. The company's prosecution profile is currently defined by this single active matter, showing a focused interaction with the patent office. For an entity in the pharmaceutical space, this 1 pending office action represents the entirety of its current effort to protect its technical innovations, concentrating all immediate prosecution risk and opportunity into one case.
The busiest examiner for the portfolio is CANTRELL, MARANDA SHURIE, who is managing 1 pending office action. This examiner is responsible for the total volume of the company's active prosecution. Because the matter is housed in a distinct art unit, the company's current pharmaceutical filings are being evaluated by a single specialized group. The reliance on a single distinct examiner for the 1 pending office action means that the company's immediate patent prospects are tied to the specific examination patterns and technical interpretations of this individual.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANTRELL, MARANDA SHURIE | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18372389 | METHODS AND SYSTEMS FOR ANNOTATING GENOMIC DATA | CANTRELL, MARANDA SHURIE | — |
| Art Unit | Apps |
|---|---|
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18372389 | METHODS AND SYSTEMS FOR ANNOTATING GENOMIC DATA | CANTRELL, MARANDA SHURIE | 1687 | §101§102§103 | Non-Final OA | — | Pending | Sep 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMartingale Labs Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Maranda Shurie Cantrell has the most, with 1 of Martingale Labs Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
